Trial Search Results

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

The purpose of this study is to examine the effects of atezolizumab, an investigational drug, for the treatment of surgically-resected non-small cell lung cancer in humans. After screening, eligible patients will be treated with chemotherapy for up to 3 months, then randomized to either atezolizumab treatment or best supportive care for one year. The study will also evaluate the ability of a biomarker, PD-L1, to predict tumor response to atezolizumab.

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting